TSG101 exposure on the surface of HIV-1 infected cells: implications for monoclonal antibody therapy for HIV/AIDS.
HIV infection remains a major global public health problem, in part because of the ability of the virus to elude antiretroviral therapies. Most conventional drugs were designed to directly target virus-encoded mechanisms. However, there is increasing appreciation that certain host-encoded molecules are comparably important for the viral life cycle and could therefore represent potential antiviral targets. Prominent among these is TSG101, a cytoplasmic molecule that is "hijacked" by HIV and used to facilitate viral budding and release. In our present report, we demonstrate thatTSG101 is uniquely exposed on the surface of HIV-infected cells and is available to antibody-based therapies. We also characterize the development of a monoclonal antibody, CB8-2, which reduces virus production from infected cells. These studies demonstrate the potential of TSG101-directed antibodies to combat HIV/AIDS.
Diaz
Leyla
L
Mao
Hanwen
H
Zhou
Yu
Y
Kohli
Manu
M
Cassella
Josephine
J
Santos
David
D
Fesseha
Zena
Z
Weng
Ke
K
Chen
Hanson
H
Bamba
Douty
D
Marks
James D
JD
Goldblatt
Michael
M
Kinch
Michael
M